The repeat biopsy in celiac disease: when guidelines suggest one and what the result means

Short answer

The 2025 European guideline does not call for a repeat biopsy in every adult with celiac disease; it says a follow-up biopsy is recommended in a personalized way1. It names these situations:

  1. Symptoms that persist or worsen, or lab signs of malabsorption2.
  2. New red-flag symptoms that raise suspicion of a complication2.
  3. Diagnosis after age 45 or a severe first presentation: a biopsy after 1 to 2 years on the diet may be reasonable2.
  4. Seronegative celiac disease, where follow-up biopsies are essential for accurate diagnosis and monitoring recovery2.
  5. The patient's own request for reassurance that the lining has healed2.

Published by Gluten Verdict · updated · 14 sources, each linked below

Reviewed by Mark Peter, Registered dietitian (RD), on

Packed purple duffel by a front door with a water bottle and a coat

Key points

  • The ESsCD guideline says a follow-up biopsy is not routinely necessary for all adults and should be decided case by case1.
  • In adults, neither symptoms nor blood tests reliably predict damage to the small bowel, the same guideline says3.
  • Healing can be slow: in one Mayo Clinic cohort, confirmed mucosal recovery was 34% at 2 years and 66% at 5 years42, 43.
  • Persistent symptoms or villous atrophy after 12 months or more call for systematic evaluation; the guideline says an incomplete response is often due to ongoing gluten exposure10.
  • The ESsCD guideline calls Marsh criteria semi-quantitative and says a villous-to-crypt ratio above 2.0 to 2.5 is generally considered indicative of mucosal recovery8.

A second biopsy asks a different question from the first

The biopsy that diagnoses celiac disease looks for signs of the disease in the small intestine36. NIDDK, the US National Institute of Diabetes and Digestive and Kidney Diseases, describes how it is taken: during an upper GI endoscopy a doctor passes an instrument through a flexible tube with a camera to take small pieces of tissue from the small intestine, and a pathologist examines them under a microscope35, 36. Coeliac UK adds that the person has an anaesthetic spray to numb the throat or an injected sedative27.

A follow-up biopsy asks a later question: has the lining healed on the gluten-free diet? NIDDK says that in some cases doctors may recommend additional biopsies to find out if the small intestine has healed31.

What follows reports what guidelines, charities and studies say. It is not a recommendation for any one person. Coeliac UK says the need and type of long-term follow-up, including whether to have a repeat biopsy, should be discussed and agreed between the patient and the clinician25.

Routine or selective: what the guidelines say

The 2025 guideline of the European Society for the Study of Coeliac Disease (ESsCD) says a follow-up duodenal biopsy is not routinely necessary for all adults with celiac disease. It is recommended in a personalized manner, guided by age at diagnosis, symptom severity, serological status and clinical response to the diet, and should be considered if symptoms persist or worsen. The guideline grades the certainty of the evidence behind this as low and the recommendation as conditional1.

The guideline gives its reasons. In adults, it says, neither symptoms nor serology is reliable to predict small-bowel damage, yet the need for routine follow-up biopsies is debatable because there is insufficient evidence that the practice affects clinical outcomes3.

What the studies behind that position found

A repeat biopsy is recommended but often omitted in people on a gluten-free diet, according to the background of a nationwide follow-up study of 760 patients39, 38. Its authors reported that severe disease at diagnosis predicted having a repeat biopsy and incomplete recovery, and that neither lacking a biopsy nor incomplete recovery at about one year was associated with poorer long-term outcome, with the caveat that survival bias cannot be excluded40.

A second study found that in patients with high dietary adherence incomplete villous recovery after one year did not affect the clinical response or long-term prognosis, and that a personalized approach is needed to decide the best timing of a follow-up biopsy41.

Not every study points the same way. A Mayo Clinic cohort followed adults who had a biopsy at diagnosis and at least one follow-up biopsy42. Its authors concluded that systematic follow-up with intestinal biopsies may be advisable in patients diagnosed with celiac disease as adults44.

What Coeliac UK says for clinicians

Coeliac UK's page for healthcare professionals says long-term follow-up is recommended for people who are poorly adherent to the diet or at risk of poor adherence, have not responded to the diet, or have developed complications. It adds that a validated five-point score outlined in the British Society of Gastroenterology (BSG) guidance can help determine the risk of persistent villous atrophy and help decide the need for a repeat biopsy25.

Situations that lead to a repeat biopsy

The ESsCD guideline lists common indications for a follow-up biopsy2. The table sets out those five, plus the guideline's separate call for systematic evaluation after 12 months10.

When the ESsCD guideline points to a repeat biopsy or further evaluation
SituationWhat the sources say
Symptoms persist or worsen, or labs show malabsorptionA common indication in the ESsCD guideline2. A biopsy should be considered if symptoms persist or worsen1.
Symptoms or villous atrophy persisting after 12 months or more on the dietThe guideline says this requires systematic evaluation10.
New red-flag symptomsA common indication: symptoms raising suspicion of complications2.
Diagnosed after age 45, or severe at firstA biopsy after 1 to 2 years on the diet may be reasonable to assess healing2.
Seronegative celiac diseaseFollow-up biopsies are essential for accurate diagnosis and monitoring recovery2.
The patient asks for reassurance that the lining has healedA biopsy may be performed at the patient's request2.

For people who are following the diet strictly, the guideline says the indication should be discussed with the patient, taking their preferences and choices into account4.

Markers of persistent damage in the studies

  • In the cohort used to build a risk score for persistent villous atrophy, the predictors were diagnosis at age 45 or older, a classical pattern of celiac disease, lack of clinical response to the diet and poor adherence50.
  • In the Mayo Clinic cohort, poor compliance with the diet, severe disease defined by diarrhea and weight loss, and total villous atrophy at diagnosis were strongly associated with persistent mucosal damage43.
  • The ESsCD guideline notes that patients with severe enteropathy, for example Marsh 3C, are at increased risk of incomplete histological recovery and may benefit from closer follow-up23.

Reading the pathology report: Marsh grades and the villous-to-crypt ratio

Marsh criteria are commonly used in clinical practice to assess the severity of mucosal lesions8. Coeliac UK describes the grades this way for patients28.

The Marsh scale as Coeliac UK describes it
Marsh gradeWhat the lining shows
Marsh 0Normal lining28
Marsh 1More lymphocytes, normal villi28
Marsh 2More lymphocytes, deeper depressions in the lining, normal villi length28
Marsh 3Villi becoming flattened28
Marsh 4Villi completely flattened28

Scales differ between reports. The ESsCD guideline describes the modified Marsh classification, which splits stage 3 into 3A (partial), 3B (subtotal) and 3C (total villous atrophy)19, so a report may say 3A, 3B or 3C rather than Marsh 3. The guideline says these sub-divisions have limited clinical relevance in routine practice20.

Villous height to crypt depth

The ESsCD guideline also discusses the ratio of villous height to crypt depth (Vh:Cd). It says Marsh criteria are semi-quantitative and, in research contexts, less precise than measuring this ratio, and that a ratio above 2.0 to 2.5 is generally considered indicative of mucosal recovery8. The guideline's diagnostic part states it differently: a ratio below 2 indicates villous atrophy and active disease, while treated patients typically have ratios above 321. It also notes that this kind of morphometry faces practical limitations and lacks standardisation22.

Readers of the same slide can differ. The guideline reports substantial interobserver variability in interpreting duodenal biopsies, particularly for mild or borderline changes such as Marsh I to II24. In the cohort used to build that risk score, persistent villous atrophy meant Marsh 3a or higher at the follow-up biopsy49.

How long healing takes, and what blood tests can say

The ESsCD guideline says healing of the duodenal mucosa is generally expected around one year after starting the diet, but the share of patients reaching full histological recovery ranges widely, from approximately 50% to 83% after 1 to 5 years7.

In the Mayo Clinic cohort of adults with a diagnostic and a follow-up biopsy, the Kaplan-Meier rate of confirmed mucosal recovery was 34% at 2 years and 66% at 5 years. Most patients (82%) had some clinical response to the diet, but it was not a reliable marker of mucosal recovery42, 43.

The ESsCD guideline describes slow-responsive disease: some patients show slow clinical, serological or histological recovery despite confirmed adherence, and improvement may take months to years, especially with longstanding disease or severe baseline damage13. It adds that assessment of persistent villous atrophy should be done with a follow-up biopsy, because healing may be delayed despite symptom resolution, particularly in older adults14.

What antibody tests can and cannot say

  • NIDDK says antibodies, which are higher in untreated celiac disease, typically return to normal after treatment32.
  • The ESsCD guideline says a decline in IgA anti-TG2 can be seen as early as 2 to 4 weeks on the diet and in the majority normalizes within about 12 months, with strong variation between people6.
  • In follow-up, a positive result suggests poor adherence or gluten contamination, while a negative result does not confirm strict adherence and is not a reliable marker of villous atrophy5.
  • Coeliac UK, summarising the BSG guideline, says the tTG blood test used in isolation is not a good indicator of gut healing or dietary adherence26.

If the repeat biopsy still shows damage

The ESsCD guideline says an incomplete response is often due to ongoing gluten exposure, but may also indicate slow-responsive disease, refractory celiac disease, initial misdiagnosis or concurrent conditions. Persistent symptoms or villous atrophy after 12 months or more requires systematic evaluation10. The American College of Gastroenterology's 2023 guideline says patients with nonresponsive celiac disease require a systematic workup to rule out specific conditions, especially unintentional gluten contamination37.

The ESsCD sequence for a symptomatic adult on the diet:

  1. Verify the original diagnosis and assess for gluten exposure11.
  2. If adherence is confirmed, proceed with follow-up histology and evaluate for alternative or overlapping conditions, such as functional disorders, other GI diseases, refractory celiac disease or malignancy, using a multidisciplinary approach11.

The guideline puts gluten exposure first: it says intentional or inadvertent exposure accounts for up to 80% of persistent symptoms12. It says adherence can be assessed through clinical evaluation, serology and structured dietary review by a specialized dietitian, and that detection of gluten immunogenic peptides (GIPs) in stool or urine can be considered as an objective measure of recent gluten intake18. Coeliac UK likewise says diagnosing non-responsive celiac disease requires dietary assessment for ongoing gluten ingestion, a review of the diagnosis and exclusion of other conditions29.

NIDDK says that in about 20 percent of people with celiac disease, symptoms continue or come back on the diet33, and lists small amounts of gluten, other health problems and refractory celiac disease as possible causes34.

Slow healing versus refractory disease

The ESsCD guideline defines refractory celiac disease (RCD) as persistence or recurrence of symptoms and villous atrophy after at least 12 months on a strict diet, in the absence of other causes16. It calls RCD a rare complication, affecting approximately 0.3% to 2% of adult patients, with most population-based studies suggesting a prevalence closer to 1% or less17.

Coeliac UK says there are two types, distinguished by the absence (type 1) or presence (type 2) of an aberrant population of intraepithelial lymphocytes, and that type 2 carries an increased risk of malignancy, particularly enteropathy-associated T-cell lymphoma30. When villous atrophy persists despite confirmed adherence, the ESsCD guideline says refractory disease and malignant complications should be evaluated, and that this evaluation should be done in specialised centres15.

What cohorts report about persistent damage

In a population-based cohort of 7625 patients with a follow-up biopsy, 3308 (43%) had persistent villous atrophy45. Compared with mucosal healing, persistent villous atrophy was associated with an increased risk of lymphoproliferative malignancy (hazard ratio 2.26, confidence interval 1.18 to 4.34); the study had no data on dietary adherence46, 47.

In a multicentre cohort, 694 of 2211 patients (31%) had a follow-up biopsy, and 157 of those 694 (23%) had persistent villous atrophy. Risk of complications (hazard ratio 9.53) and of mortality (hazard ratio 2.93) was increased in them48. The authors developed a score to identify patients at risk of persistent villous atrophy and in need of histological reassessment and closer follow-up51. Both cohorts describe people who had a follow-up biopsy45, 48, and in the 760-patient study severe disease at diagnosis predicted having a repeat biopsy40.

What a normal or improved result does and does not tell you

The ESsCD guideline calls histological healing of the duodenal mucosa a key milestone, because it underpins restoration of normal intestinal absorption9. In the population-based cohort of patients with a follow-up biopsy, the risk of lymphoproliferative malignancy was higher than in the general population overall, and lower among patients with mucosal healing (standardized incidence ratio 1.50, confidence interval 0.77 to 2.62) than among those with persistent villous atrophy (3.78, confidence interval 2.71 to 5.12)46.

What a biopsy does not do is replace the other ways of watching the diet. The guideline says adherence is assessed through clinical evaluation, serology and structured review by a specialized dietitian, and that duodenal biopsy, while the definitive method for assessing mucosal healing, is not routinely required for adherence monitoring alone18. Symptom relief is no stand-in either: in the Mayo Clinic cohort it was not a reliable marker of mucosal recovery43.

Questions people ask

Do I need a second biopsy after going gluten-free?

Not routinely, according to the 2025 ESsCD guideline: it is recommended in a personalized way and should be considered if symptoms persist or worsen1.

Can a blood test replace a repeat biopsy?

The ESsCD guideline says that in adults neither symptoms nor serology is reliable to predict small-bowel damage3. Coeliac UK says the tTG test used in isolation is not a good indicator of gut healing26.

How long does the gut take to heal?

The ESsCD guideline says healing is generally expected around 1 year, but the share with full recovery ranges from approximately 50% to 83% after 1 to 5 years7. A Mayo Clinic cohort found 34% at 2 years and 66% at 5 years42, 43.

Does persistent villous atrophy mean refractory celiac disease?

Not by itself. The ESsCD guideline lists ongoing gluten exposure first among the causes, then slow-responsive disease, refractory disease, misdiagnosis and concurrent conditions10, and defines refractory disease as persistence after at least 12 months on a strict diet in the absence of other causes16.

What do Marsh 3A, 3B and 3C mean?

In the modified Marsh classification, stage 3 is split into 3A (partial), 3B (subtotal) and 3C (total villous atrophy)19.

More in Gut science, healing and treatment research

Sources